Howard Liang, Ph.D.
CFO and Chief Strategy Officer
Disclosures

• Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding investigational drug candidates and clinical trials and the status and related results thereto, as well as those regarding continuing and further development and commercialization efforts and transactions with third parties. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BeiGene’s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which BeiGene does business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational drug candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from BeiGene’s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our drug candidates, final and quality controlled verification of data and the related analyses, the expense and uncertainty of obtaining regulatory approval, including from the FDA, NMPA (formerly CFDA/CDA) and EMA, the possibility of having to conduct additional clinical trials and BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services. Further, even if regulatory approval is obtained, pharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in BeiGene’s filings with the Securities and Exchange Commission (SEC). The reader should not place undue reliance on any forward-looking statements included in this presentation or in the accompanying oral presentation. These statements speak only as of the date made, and BeiGene is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

• Some of the clinical data in this presentation relating to BeiGene’s investigational drug candidates is from early phase, single-arm trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-to-head trials between BeiGene’s investigational drug candidates and other products. BeiGene is still conducting clinical trials and, as additional patients are enrolled and evaluated, data on BeiGene’s investigational drug candidates may change.

• This presentation and the accompanying oral presentation contains data and information obtained from third-party studies and internal company analysis of such data and information. BeiGene has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is subject to the same qualifications noted above.
Agenda

Welcome – Howard Liang
Opening Comments – John V. Oyler
BeiGene’s China Business – Xiaobin Wu
The Facts – Howard Liang
Insider Sales – Howard Liang
Our Investments – John V. Oyler
Q&A
John V. Oyler
Chairman, Co-Founder & CEO
BeiGene At-A-Glance

Fully-integrated global biotech company with internal capabilities in research, clinical development, commercialization and manufacturing

2,700+ employees 10 offices on 4 continents.
Trials in 34 countries and regions
- ~300 research
- 1000+ global clinical
- 600+ commercial

Key catalysts in 2019/20 including expected product approvals and up to 10 Phase 3 or potentially registration-enabling trial readouts could further transform the company

Broad product portfolio and pipeline
- Three wholly owned late-stage candidates including two currently under regulatory review
- 26 Phase 3 or potentially registration-enabling trials ongoing, 60+ studies in total
- Balanced portfolio of 13 clinical or commercial stage assets including 6 internally developed and 7 in-licensed
- Growing commercial business, from $15.6M in 4Q:17 to $58.1M in 2Q:19 since transition to BeiGene
Our Leadership Team

Attracting global talent to build a world-class team

John V. Oyler
Founder, CEO, and Chairman
BioDuro, Galenea, Telephia, Genta, McKinsey & Company

Xiaodong Wang, Ph.D.
Founder and Chairman SAB
NIBS: National Institute of Biological Sciences in Beijing, UT Southwestern Medical Center, Howard Hughes Medical Institute, National Academy of Sciences

Xiaobin Wu, Ph.D.
GM of China, President
Pfizer
Wyeth
Bayer

Howard Liang, Ph.D.
CFO and Chief Strategy Officer
Leerink
Abbott

Jane Huang, M.D.
Chief Medical Officer, Hematology
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Yong Ben, M.D.
Chief Medical Officer, Immuno-Oncology
BioAtla
AstraZeneca

Eric Hedrick, M.D.
Chief Advisor
Genentech
Pharmacyclics
Epizyme

Anita Wu
Chief Commercial Officer, Greater China
Sanofi
AstraZeneca
Pfizer

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Scott Samuels, Esq.
SVP, General Counsel
ARIAD
Mintz Levin

Todd Yancey, M.D.
SVP, Global Medical Affairs & New Market Development
BioMarin, Medivation
Clovis Oncology, Onyx

Eric Liang, Ph.D.
CFO and Chief Strategy Officer
Leerink
Abbott

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck

Jane Huang, M.D.
Chief Medical Officer
Genentech
Acerta

Wendy Yan
SVP, Global Head of Regulatory Affairs
Bayer
AstraZeneca

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development
UT Southwestern Medical Center

Josh Neiman
Head of U.S. Commercial
Flatiron Health
Onyx Pharmaceuticals
Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck
Xiaobin Wu, Ph.D.
General Manager of China & President of BeiGene, Ltd.
From our Form 10-K, “Revenues from product sales are recognized when there is a transfer of control from the Company to the distributor. The Company determines transfer of control based on when the product is delivered, and title passes to the distributor. Provisions for estimated reductions to revenue are provided for in the same period the related sales are recorded and are based on the sales terms, historical experience and trend analysis. To date, sales returns have not been significant.”
AgileSC sales represent distributor sales to hospitals. This is self-reported by distributors and audited by an independent third party. Sales data is from over 420 distributors. There is typically a ~10-15% difference between distributor data and net reported sales due to geographic expansion and in-market sales data capture because:

- Distributors need to build the minimum inventory during expansion/growth periods and to ensure appropriate supply
- The data does not capture sales data in territories where there is no sales rep or smaller markets. This is typically 10-15% for a branded oncology drug.

*Adjusted for a $2.3 mln reduction recorded to gross revenue in Q4 2017 for rebates to product that was within the channel upon NRDL inclusion.
Building Oncology-Focused Commercial Footprint in China

A growing 600+ top innovative oncology commercial team targeting to cover 800 – 1,000 hospitals in China

1 As of December 31, 2018
Howard Liang, Ph.D.
CFO and Chief Strategy Officer
Our structure in Guangzhou to manufacture, develop, and commercialize PD-1 in China

- IP owner of PD-1 in China
- Distributor once PD-1 approved
- Requires periodic capital raises to fund PD-1 development in China (work done by BeiGene Shanghai) and BPG
- Acquired distribution licenses through acquisition of Huajian to enable it to sell PD-1 in China
- Has an intercompany loan with BPG ($25mln to enable it to make payment to BI for a dedicated production line)

BeiGene, Ltd.

BeiGene, Hong Kong Co, Limited

BeiGene Biologics Co, Ltd

BeiGene (Shanghai) Co, Ltd

- Clinical operations entity which holds MAH for PD-1 in China
- 240 employees
- Transferred into Biologics as part of the JV agreement

BeiGene Guangzhou Biologics Manufacturing Co

- State-of-the-art biologics manufacturing facility
- Grand opening September 27, 2019
- Will produce clinical PD-1 in the near term and other biologics in the future

BeiGene (Guangzhou) Co Ltd (BGC)

BeiGene Pharmaceuticals Guangzhou Co (BPG)

- Former Huajian entity which holds a drug distribution license, enabling us to sell PD-1 in China
- Entity responsible for commercializing PD-1
- Made $25mln payment to BI for dedicated production line
- Recorded $25mln payment as a non-current asset, since the value will be credited back as a discount on future purchases from BI
Role of BeiGene Guangzhou Company (BGC)

- Entity that funds the development of tislelizumab and will distribute it in China
- Increase of registered capital and expenses needed to provide funding for tislelizumab clinical trials in China
- Acquisition of Huajian Pharmaceutical to obtain the required Good Supply Practice (GSP) license and Drug Distribution License (DDL)
  - In preparation of commercialization of tislelizumab in China (non-current asset)
  - Payment for BI capacity expansion of production line for manufacturing tislelizumab, for which we are entitled to reduced product cost from BI in the future
- Registered address of BGC
  - Address on file is for registration
  - We have office at a different location shared by BGC, our GZ Biologics JV and manufacturing facility employees
John V. Oyler
Chairman, Co-Founder & CEO
Peer Company R&D Spending vs. Number of Ph3 Trials -1H19

**Note**: Active Ph3 trials include enrolling trials and active trials but not enrolling, not including completed or inactive trials; source: company financial report, clinicaltrial.gov, chinadrugtrials.org.cn

\[ y = 40.281x + 19.937 \]

\[ R^2 = 0.7538 \]
Thank you
Q&A